Floatz logo

PROLACTIN G129R

Peritoneal Cancer

Oncolix, Inc.protein_peptidePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking University
Phase 2BB
Docetaxel
University of Pittsburgh
Phase 2BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Rucaparib
pharmaand GmbH
Phase 3BB

View all 50 →

Same molecule, other indications

PROLACTIN G129R is also rated in:

fallopian tube cancerDormant
C
Indicative ·
37 / 100
View asset →
ovarian cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →